EUVIMEDEUVIMED entdecken
Crossref

Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”

Baoqing Chen iD, Zimeng Li iD, Xingyuan Cheng, Mian Xi iD

Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3282-3284

DOI: 10.1200/jco-26-01677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Baoqing Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Baoqing Chen, MD, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer I…. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Baoqing Chen, MD, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China, Department of Radiation Oncology, Sun Yat-…

ORCID-Profile: Baoqing Chen, Zimeng Li, Mian Xi

Zitieren

APA

Chen, B., Li, Z., Cheng, X., & Xi, M. (2026). Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”. Journal of Clinical Oncology, 44(33), 3282-3284. https://doi.org/10.1200/jco-26-01677

Vancouver

Chen B, Li Z, Cheng X, Xi M. Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”. Journal of Clinical Oncology. 2026;44(33):3282-3284. doi:10.1200/jco-26-01677

BibTeX
@article{Chen2026,
  author = {Chen, Baoqing and Li, Zimeng and Cheng, Xingyuan and Xi, Mian},
  title = {Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {33},
  pages = {3282--3284},
  doi = {10.1200/jco-26-01677}
}
Kostenlos starten →